Prostate Cancer Trials
Phase 3 Clinical Trial in 2nd-line Metastatic Castrate-Resistant Prostate Cancer (CRPC)
AFFINITY is a company-sponsored, randomized Phase 3 trial evaluating whether custirsen, when combined with the second-line chemotherapy, Jevtana® (cabazitaxel), has the potential to improve survival outcomes for prostate cancer patients who have progressed following treatment with docetaxel. Patients were randomly selected to receive Jevtana plus prednisone with or without custirsen therapy.
The trial enrolled 634 men with metastatic CRPC and was conducted throughout North America, Europe, Russia and Australia.
Final survival results were announced in August 2016.
Phase 2 Clinical Trial in Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Pacific™ is an investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in men with metastatic CRPC who are experiencing rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). Pacific aims to evaluate the potential benefit of adding apatorsen to Zytiga plus prednisone for patients with metastatic CRPC by measuring the treatments’ ability to extend time without disease progression. The trial is sponsored by the Hoosier Oncology Group.
NOW ENROLLING: Learn more about the Pacific Trial.
Zytiga® is a registered trademark of the Johnson & Johnson Corporation
Jaime Welch, Vice President, Marketing & Corporate Communications
“For many patients with advanced disease, treatment options are limited and clinical trials are an important option to consider. We work with clinicians and institutions across the world to ensure that patients are aware of our trials as an option as they continue their fight against cancer."